Achaogen is dedicated to addressing serious medical needs caused by the development of bacterial resistance to antibiotics.
According to the CDC, over 70% of hospital bacterial infections are resistant to one or more classes of antibacterial drugs. In the United States alone, these infections cause more than 90,000 deaths per year and result in $4.5 billion in excess healthcare costs.
Achaogen exists to apply its anticipatory science to the creation of novel medical therapies to combat tomorrow’s drug-resistant pathogens, specifically, the next generation of pan-resistant bacteria, including infections caused by Gram-negative pathogens and methicillin-resistant Staphylococcus aureus (MRSA). This scientific strategy represents a novel approach to addressing the global bacterial-resistance crisis.
New hires at Achaogen
-
Associate Director, Regulatory Operations
Came from...
Genentech, Director, Regulatory Operations
-
Research Associate II
Came from...
Walter Reed Army Institute of Research, Intern Research Assistant
Achaogen Activity on LinkedIn
-
Achaogen has a new Research associate
Meghana Kanakamedala is now Research associate
-
Achaogen has a new Helpdesk / Informatics Support
Wirt Winfred Balasta is now Helpdesk / Informatics Support
